HOME >> BIOLOGY >> NEWS
Gladstone scientists identify critical gene factor in heart development

SAN FRANCISCO, CA -March 29, 2007 -- Researchers at the Gladstone Institute of Cardiovascular Disease (GICD) announced they have identified a critical genetic factor in the control of many aspects of heart form and function. As reported in the journal Cell, scientists in the lab of Deepak Srivastava, MD, have successfully deleted a genetic factor, called a microRNA, in animal models to understand the role it plays in cardiovascular differentiation and development.

MicroRNAS, or miRNAs, seem to act as rheostats or "dimmer switches" to fine-tune levels of important proteins in cells. To learn how microRNAs do this, the team led by Dr. Srivastava, deleted the gene responsible for one microRNA in mice and examined the effects of its loss on heart development and maintenance. "Knocking out" a gene is a favorite method for figuring out what a particular gene does in a cell by selectively removing it.

"Development of the heart requires very careful regulation of many factors, and that's one reason that microRNAs are so exciting to us," said Dr. Srivastava, GICD Director. "By knocking out the gene for one miRNA, we could determine exactly what it contributes to that complex process."

MicroRNAs exert their control by stopping protein production after the genes have directed them to be made. Previously, it was thought that all the control was at the level of the genes. Although only 20-22 nucleotides long, the microRNAs bind to the much longer messenger RNAs and prevent their blueprint for building a protein from being used. They typically prevent many messenger RNAs from making proteins and therefore can affect myriad events.

The Gladstone team looked at one particular microRNA, miR-1-2, that was active specifically in the heart. A closely related and redundant microRNA miR-1-1 could not fully compensate for loss of miR-1-2. The team found that loss of miR-1-2 affected many functions in the heart, including heart morphogenesis and contro
'"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
29-Mar-2007


Page: 1 2

Related biology news :

1. Gladstones Deepak Srivastava receives E. Mead Johnson Award for achievement in pediatrics
2. Gladstone scientists prove neurons produce Alzheimers-linked apolipoprotein E
3. Gladstone Institutes receives funding for training grant from stem cell institute
4. Gladstone researchers hone in on differentiation of heart stem cells
5. Gladstone study links Alzheimers with toxic protein fragments
6. Gladstone researchers identify new drug target for Alzheimers disease
7. Gladstone Institutes assists with Exploratorium stem cell exhibit
8. CIRM awards $2.4 million training grant to the Gladstone Institutes
9. Gladstone investigators discover how resting T cells avoid HIV infection
10. Gladstone investigator Steve Finkbeiner wins prestigious Lieberman Award
11. Gladstone building honored with San Francisco Business Times award

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... Feb. 7, 2017  Aware, Inc. (NASDAQ: AWRE ... reported financial results for its quarter and year ended December ... of 2016 was $3.9 million compared to $6.9 million in ... quarter of 2016 was $0.6 million compared to $2.6 million ... fourth quarter of 2016 was $0.5 million, or $0.02 per ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... -- Symic Bio, a biopharmaceutical company focused on matrix ... announced today the completion of enrollment for the SHIELD ... trial will evaluate the safety and efficacy of SB-030, ... restenosis following angioplasty. "We,re pleased to ... Nathan Bachtell , M.D., Chief Medical Officer of ...
(Date:2/24/2017)... ... , ... FireflySci, Inc is an explosive small business that continues to grow ... bringing their powerful cuvette and spectrophotometer calibration to the spectroscopy world. ... on as they add yet another mark on the global map. , With distributors ...
(Date:2/24/2017)... 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a ... Key Opinion Leader event to highlight new clinical data ... presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and ... be held in-person and via live webcast on Tuesday, ... PST at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... drive their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of ...
Breaking Biology Technology:
Cached News: